TOKYO -- Japanese researchers performed the world's first transplant of retina cells made from donor-derived induced pluripotent stem (iPS) cells into a patient's eye late last month. Compared to using the patient's own cells to create the iPS cells, the cost and time required to prepare for a surgery can be reduced to less than one tenth, which could make iPS cell treatments more accessible to patients.
Science
iPS cell stockpiling system brings treatment closer to patients
Time, costs can be trimmed, but risk of rejection remains
Researchers perform the world's first transplant using donor-derived iPS cells at Kobe City Medical Center General Hospital.
Read Next
Latest on Science
